Schering-Plough Corporation today announced a license agreement between Nobilon, Schering-Plough's human vaccine business unit, and the World Health Organization (WHO) to provide access to pandemic influenza vaccine manufacturing technology to developing countries...Under the agreement…Nobilon has granted WHO a non-exclusive license to develop, register, manufacture, use and sell seasonal and pandemic live, attenuated, influenza vaccines (LAIV)…WHO will be permitted to grant a sub-license to vaccine manufacturers in developing countries…who will [then] be able to provide vaccines to the public sector of developing countries royalty-free.